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Abstract: The Western world appears to be in the midst of the third great gout epidemic of all 
time. In this century, gout is increasing in prevalence despite an increased understanding of its 
risk factors and pathophysiology, and the availability of reasonably effective treatment. The 
main cultural factors responsible for this appear to be diet, obesity, ethanol use and medications. 
Excess fructose consumption is a newly recognized modifiable risk factor. The debate has been 
renewed concerning hyperuricemia as an independent risk factor for renal insufficiency and 
cardiovascular disease. Prevention is still rooted in lifestyle choices. Existing treatments have 
proven to be unsatisfactory in many patients with comorbidities. New treatments are available 
today and on the horizon for tomorrow, which offer a better quality of life for gout sufferers. 
These include febuxostat, a nonpurine inhibitor of xanthine oxidase with a potentially better 
combination of efficacy and safety than allopurinol, and investigational inhibitors of URAT-1, 
an anion exchanger in the proximal tubule that is critical for uric acid homeostasis. New abortive 
treatments include interleukin-1 antagonists that can cut short the acute attack in 1 to 2 days in 
persons who cannot take nonsteroidal anti-inflammatory drugs, colchicine or corticosteroids. 
Lastly, newer formulations of uricase have the ability to dissolve destructive tophi over weeks 
or months in patients who cannot use currently available hypouricemic agents. Diagnostically, 
ultrasound and magnetic resonance imaging offer advanced ways to diagnose gout noninva-
sively, and just as importantly, a way to follow the progress of tophus dissolution. The close 
association of hyperuricemia with metabolic syndrome, hypertension and renal insufficiency 
ensures that nephrologists will see increasing numbers of gout-afflicted patients.
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Introduction
“Be temperate in wine, in eating, girls, and cloth, or the Gout will seize you and 
plague you …”
Benjamin Franklin 1706–1790
Studies on the prevalence of gout suggest that we are in the midst of the third great 
gout epidemic of the Western world.1,2 Some of the reasons for this are of particular 
concern to nephrologists who so commonly must treat gout in persons with renal 
disease. Reasons for the increase in the prevalence of gout in the past 50 years include 
first and foremost an increase in the prevalence of metabolic syndrome, which in 
turn reflects the increase in the average weight of the Western population. Whereas 
during the golden age of both the Roman and British empires gout was associated 
with drinking and to a lesser extent lead poisoning,3–5 in the present age gout is 
largely associated with obesity.6–9 Other factors are iatrogenic, such as an increase International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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in the use of low-dose aspirin (but not high-dose aspirin),10 
diuretics (very useful medicines in their own right)9 and 
other medications such as cyclosporine, and an increase in 
the number of organ transplants.
The purposes of this review are several-fold: 1) We will 
review the first Food and Drug Administration (FDA)-approved 
hypouricemic agent in 40 years, one that seems to be particularly 
useful in patients with renal insufficiency. 2) We will review the 
current data on uricase, a potential treatment for gout that (as the 
time of writing) has been resubmitted to the FDA for possible 
approval, and is a treatment that could be particularly useful 
for those with renal insufficiency. 3) We will review advances 
in the understanding of both crystal-induced inflammation and 
renal handling of uric acid. 4) We will review recent additions 
to the body of knowledge that suggests that hyperuricemia itself 
contributes independently to the development of hypertension, 
renal insufficiency and cardiovascular disease. 5) We will 
review evidence that the two currently available interleukin-1 
(IL-1) inhibitors are effective for treatment/prophylaxis of gout 
attacks. 6) We will review musculoskeletal ultrasound as a 
useful imaging technique for both the diagnosis of gout and to 
follow the effects of hypouricemic therapy. 7) We will review 
evidence suggesting that fructose overconsumption contributes 
disproportionately to the development of hyperuricemia.
Several factors make the treatment of gout worth 
reviewing for nephrologists. As mentioned, the prevalence 
is increasing. Secondly, for the first time in 40 years a 
new, oral hypouricemic agent (febuxostat; Uloric®, Takeda 
Pharmaceuticals) has been approved in the United States 
(US), and it seems to be particularly useful in those with 
renal insufficiency, although data are still limited in this 
population.11 Thirdly, the goal of safely and effectively 
administering uricase to humans may finally be within 
reach.12,13 Fourthly, nonsteroidal anti-inflammatory drugs 
(NSAIDs) (never popular among nephrologists, yet a 
mainstay of treatment for gout among other physicians) are 
now even less popular because of their recently discovered 
cardiovascular risks.14 Fifthly, the debate as to whether 
asymptomatic hyperuricemia contributes directly to kidney 
disease and to cardiovascular risk is again coming to the 
forefront.15,16 Lastly, misconceptions about the treatment 
of gout unfortunately still abound even among physicians.17 
Long-term management of gout with lifestyle changes and 
3 different classes of medications (those for treatment of the 
acute attack, those for prophylaxis of attacks and those that 
reduce body burden of uric acid) can be something of an art. 
Diagnostically, ultrasound has emerged as a useful tool both 
to diagnose gout and to follow the effects of hypouricemic 
treatment.18,19
Patient perspectives
The marked increase in the prevalence of gout in recent years 
has sparked a number of studies on the quality of life of gouty 
patients. How do we do at treating gout?
Several studies have documented a lower quality of life 
among gouty patients. A recent study of gouty patients found 
that the PCS (Physical Component Summary of the SF-36) was 
approximately 10 points lower than for the general population. 
This is twice the threshold of what is considered clinically mean-
ingful. One conclusion of the study was that the current treatment 
of gout appears to be suboptimal in that nearly half of the patients 
in the study were experiencing three or more gout flares per year, 
despite .80% of the patients chronically receiving allopurinol. 
It was hypothesized that physicians may not view the impact of 
gout nearly as severely as do patients.20 It is not entirely clear 
that this is due to gout alone. Gouty patients have on average a 
larger number of comorbidities. This was documented recently 
among veterans21,22 but in other studies lower quality persists 
after adjustment for comorbidities.23
A recent review of 2 systematic reviews performed by 
the Cochrane Musculoskeletal Group highlighted the lack of 
randomized controlled trials regarding treatment options for 
acute gout. One conclusion was that colchicine provided a 
lower quality of life because it almost always causes diarrhea 
at effective doses, and has a slower onset of action at doses 
that avoid gastrointestinal distress.24
As pointed out by Kim and Choi, recent studies suggest 
that the majority of gouty patients are not adequately man-
aged with currently available gout treatments.25 Shulten found 
that physicians do not recommend adequate dietary changes 
to many persons with gout.26
It has been further pointed out that serum uric acid is the 
usual endpoint used in gout treatment trials,25 whereas the 
FDA is now recommending use of patient-reported outcome 
instruments as effectiveness endpoints in clinical trials. 
Patients are more interested in the number and severity of 
gout attacks rather than keeping their uric acid level low. 
This helps to explain the often poor patient compliance with 
hypouricemic therapy. It is worth noting in this regard that 
(despite our efforts at education) patients often perceive 
hypouricemic therapy as causing more gout instead of less, 
adding to noncompliance.
In summary, there continue to be abundant opportunities 
to improve the outcomes of this disease.
Risk factors
The prevalence of gout increases approximately four-fold to 
4.1% by the age of 75 years.27 The risk of developing gout is 
closely related to the serum uric acid (sUA) level,28 yet most International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
147
Treatment of gout
persons with hyperuricemia never develop clinically evident 
gout. In one large study, the 5-year risk of gout varied from 
0.6% for those with a serum uric acid level  7 mg/dL to 
30.5% for those with a level $10 mg/dL. The prevalence of 
hyperuricemia varies with factors such as age, gender, body 
mass index, blood pressure and renal function. Women are 
relatively protected until menopause, at which time the inci-
dence of gout increases, a phenomenon that is attributed to 
loss of estrogen effect (with resulting increase in serum uric 
acid level), but the exact pathophysiology is unclear.29,30
Gout is closely associated with metabolic syndrome 
consisting of insulin resistance, obesity, hypertension and 
hypertriglyceridemia.1 The magnitude of this association 
bears emphasis. In one cohort study, the prevalence of the 
metabolic syndrome was 43.6% in those with gout versus 
5.2% in the general population.31 Both hyperuricemia and 
metabolic syndrome are associated with abdominal girth as 
an independent risk factor.32 Hypertriglyceridemia (but not 
isolated hypercholesterolemia) has been reported in 75% to 
80% of gouty patients,33 and is only partially explained by 
obesity and ethanol consumption. Hypertension may also 
be a risk factor for hyperuricemia. Hyperuricemia occurs in 
22% to 38% of hypertensive patients before treatment and 
the prevalence is further increased by diuretic use.
While type 2 diabetes is a known risk factor for meta-
bolic syndrome and for gout, it appears that those with a 
higher degree of insulin resistance are more at risk.34 Some 
of the recognized risk factors for hyperuricemia are given 
in Tables 1 and 2.
Cyclosporine is a major factor in the surprisingly high 
prevalence of gout among heart transplant patients, as high 
as 24% in one study.51–53
One of the most recent and fascinating developments in 
the understanding of risk factors for gout is the hypothesis 
that there is a strong correlation between consumption of 
fructose and development of both metabolic syndrome and 
hyperuricemia.50,54 Rats fed a high-fructose diet develop 
hyperuricemia, hypertension and afferent arteriopathy that 
are ameliorated (including improvement in histomorphology) 
by allopurinol, febuxostat or benzbromarone, and there is 
accumulating evidence in humans.55,56 On the other hand, the 
view that current levels of fructose intake are reasonably safe 
is eloquently argued by White.57,58
The safety of high fructose corn syrup (HFCS) was never 
seriously questioned until recently because the composition is 
very similar to that of sucrose, except for the presence of the 
disaccharide bond in sucrose.58 HFCS contains sugars mainly 
in the form of monosaccharides. The most commonly used 
high fructose products are HFCS-42 and HFCS-55, which 
contain 42% and 55% fructose, respectively, with the balance 
of the carbohydrates consisting mainly of glucose. Sucrose 
is a disaccharide consisting of equal parts (50% each) of 
fructose and glucose. The term “high fructose corn syrup” is 
used to distinguish it from simple corn syrup which contains 
carbohydrate almost exclusively in the form of glucose.
How would excessive fructose intake cause hypertension? 
As intriguingly detailed by Soleimani,59 increased dietary 
fructose stimulates both salt and fructose absorption from the 
small intestine, but also reabsorption of sodium in the kidney 
proximal tubule. This is thought to be due to the presence of 
the same fructose-stimulated transporter mechanisms in both 
locations. In animal experiments, fructose-induced hyperten-
sion could be abrogated by feeding a low-salt diet. Soleimani 
Table 1 Some recognized risk factors for hyperuricemia
Purine over-ingestion1
Metabolic syndrome
ethanol use35
Renal insufficiency
Filipino ancestry36
Psoriasis37
Myeloproliferative38 and lymphoproliferative39 disorders
Chronic lead poisoning40
Dehydration
The postoperative state41
Critical illness with metabolic acidosis42
Sarcoidosis43
Hyperparathyroidism44
Ketosis45
Polycystic kidney disease46
Down syndrome47
Hypoxanthine-guanine phosphoribosyl-transferase deficiency 
(Lesch–Nyhan syndrome when homozygous)48
Phosphoribosylpyrophosphate synthetase overactivity49
Glucose-6-phosphatase deficiency (von Gierke’s disease)49
Fructose 1-phosphate aldolase deficiency50
Table 2 Drugs associated with hyperuricemia
Diuretics (loop and thiazide types)
Low-dose aspirin
Cyclosporine, tacrolimus
ethanol
ethambutol
Pyrazinamide
Ritonavir, darunavir, didanosine
Levodopa
Nicotinic acid, niacin
Pancreatic enzymes
Rituximab
Basiliximab
Teriparatide
Filgrastim
Sildenafil
Diazoxide
Cytotoxic chemotherapyInternational Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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argues that increased dietary fructose and salt are additive in 
their effects, and optimal blood pressure control for the hyper-
tensive population would require reduction of both nutrients.
Does fructose cause hyperuricemia in humans as it does in 
animals? Prospective data are difficult to find. Akhavan and 
colleagues administered 300 kcal sugar loads to normal sub-
jects. The sugar loads consisted of different ratios of glucose to 
fructose (G/F). Sucrose was also used. A sugar load consisting 
of 20% glucose and 80% fructose is designated as G20/F80. 
Uric acid levels began to rise within 15 minutes after the sugar 
loads. By 45 minutes, uric acid level rose by ∼61 µmol/L 
(∼1.02 mg/dL) in the G20/F80 group, but only approximately 
half that in the sucrose group and in the G50/F50 group, 
although the difference was not statistically significant, per-
haps because of the small sample size (n = 7). Baseline mean 
uric acid level in this study was 295.9 µmol/L (∼5.0 mg/dL).60 
Nevertheless, definitive prospective data indicating that long-
term fructose overconsumption contributes to long-term hype-
ruricemia in human populations are still lacking.
Is renal insufficiency of any cause a risk factor for gout? 
This has been a controversial question. Because of the com-
plex handling of uric acid by the kidney (see Pathophysiology 
below), it seems to depend on the cause of the renal insuffi-
ciency. The incidence of kidney stones is markedly reduced in 
many cases of renal insufficiency.61 Diseases that are primarily 
glomerular do not seem to increase the incidence of gout until 
glomerular filtration rate (GFR) falls to ∼15 mL/min because 
of a compensatory increase in tubular secretion resulting in a 
markedly increased fractional excretion of uric acid.61,62 Tubular 
diseases, on the other hand, can either increase or decrease the 
incidence of gout depending on which part of the tubule is 
affected. Other factors that may contribute to the relatively low 
rate of hyperuricemia and gout in patients with chronic kidney 
disease (CKD) include lower protein intake and increased 
intestinal clearance of uric acid. As with gouty patients with 
normal renal function, most patients with CKD and gout are 
“underexcretors” of uric acid for their level of serum creati-
nine.62 The question as to whether CKD is a risk factor for 
hyperuricemia was recently reviewed by Feig who looked at 
11 studies published in the past several years. He noted that 
7 studies supported such an association while 4 did not.63
Role of uric acid in cardiovascular 
and renal disease
In addition to epidemiologic studies that have consis-
tently indicated that hyperuricemia itself is a risk factor for 
cardiovascular disease rather than an innocent bystander, 
additional lines of experimental evidence now support this 
notion. There is evidence that uric acid itself may contribute 
to vascular endothelial dysfunction and plays a “pro-oxidant” 
role. While the exact mechanisms are not known, experimen-
tal hyperuricemia in rats produced hypertension, endothelial 
dysfunction, interstitial disease and vascular smooth muscle 
proliferation.64–67
In 1982, Gibson and colleagues demonstrated that 
allopurinol treatment of a group of gouty patients with CKD 
resulted in preservation of GFR, in contrast to a control 
group.68 Avram and Krishnan recently reviewed clinical 
studies of hyperuricemia and CKD, and concluded that most 
studies show hyperuricemia to be an independent risk factor 
for the future development of CKD.69 Siu and colleagues 
published a small controlled trial that showed a trend toward 
preservation of GFR using allopurinol in hyperuricemic 
patients with mild to moderate CKD.56 A recently presented 
abstract found that long-term febuxostat improved or pre-
served GFR in gouty patients.70
There have been several critical reviews of the evidence 
linking hyperuricemia in a causative role with cardiovascular 
disease, with the conclusion being that the association seems 
reasonably strong, but is not yet definitive.71,72
Does hyperuricemia directly cause hypertension? Perhaps 
the most compelling evidence comes from animal studies 
in which induced hyperuricemia causes hypertension that 
is reversible with hypouricemic agents including febuxo-
stat, allopurinol and benzbromarone.73 In one such study, 
experimental hyperuricemia using oxonic acid (an inhibitor 
of uricase) also caused glomerular hypertrophy, afferent 
arteriolar sclerosis and macrophage infiltration.74
Prospective data in humans that definitively establish 
causality between hyperuricemia and hypertension are lack-
ing. Nevertheless, a number of such studies suggest a causal 
relationship without another likely explanation.75–78 One large 
epidemiologic study using a subset of the Multiple Risk Factor 
Intervention Trial (MRFIT) database followed for 6 years 
men who had hyperuricemia (serum uric acid .7.0 mg/dL) 
but without either hypertension or metabolic syndrome. The 
presence of hyperuricemia alone increased the risk of develop-
ing hypertension by 80% after control for other known risk 
factors.79 Epidemiological studies in children and adoles-
cents have strongly associated hyperuricemia with the later 
development of hypertension, but perhaps most interesting 
is a prospective study that used allopurinol in adolescents to 
successfully treat hypertension.80 Results have been incon-
sistent in adults. It has   therefore been hypothesized that the International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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pathophysiology of essential hypertension is still reversible 
in adolescents but becomes fixed by adulthood.
If hyperuricemia causes hypertension and cardiovascular 
disease, what is the mechanism? There may be several. The 
role of fructose has recently been highlighted as discussed 
above. Vascular reactivity (itself a part of the metabolic syn-
drome) has also been reported as a direct effect of hyperuri-
cemia. For instance, using isolated rat aorta rings, Nakagawa 
and colleagues demonstrated a striking relationship between 
uric acid level and impaired vasorelaxation in response to ace-
tylcholine perfusion.50 This effect was apparent even at physi-
ologic concentrations of uric acid for the rat (∼1.5 mg/dL). 
Data are less direct in humans. One study found serum uric 
acid to be an independent risk factor for forearm blood flow 
in patients on stable peritoneal dialysis.81
Gout has long been associated with congestive heart 
failure, with the presumed association simply being hyperu-
ricemia due to diuretic use, but recent research suggests that 
uric acid level in itself is associated with diastolic dysfunction 
and left ventricular hypertrophy (independent of any effect 
on blood pressure), and is an independent risk factor for 
congestive heart failure.82,83
Pre-eclampsia is associated with hyperuricemia, higher 
serum levels being associated with worse intrauterine growth 
retardation. Recent research suggests that elevated uric acid 
plays a role in impaired amino acid transport through the 
placenta, and may thus play a causative role.84
Pathophysiology
Renal handling of urate
There have been a number of advances in the understanding 
of the renal handling of uric acid in recent years.85 First, it is 
important to realize that the upper limit of normal for serum uric 
acid (approximately 8.0 mg/dL for men in most labs) is not at 
all related to the solubility of uric acid in serum, but is derived 
purely from population-based studies of “normal” persons. 
The upper limit of uric acid solubility in serum at physiologic 
pH and temperature is approximately 6.8 mg/dL. This level is 
much more relevant for gout. The normal body urate pool in 
men ranges from about 800 to 1500 mg with a daily turnover of 
approximately two-thirds.86 The body pool of urate is expanded 
in gouty patients, both because of hyperuricemia and also 
because of deposition of monosodium urate (MSU) in tissues 
(which may be asymptomatic for many years).
Most (85% to 90%) of gouty patients are defined 
as “underexcretors”.87 In this group, measurements of 
endogenous uric acid production is normal, so it is assumed 
that the kidney is not excreting enough uric acid to maintain 
serum levels in the normal range (6.8 mg/dL). It could also 
be said that the kidney excretes normal amounts of uric acid 
only when the serum level is elevated.
Uric acid is freely filterable at the glomerulus. Almost all 
of the filtered uric acid is then reabsorbed in the S1 segment 
of the proximal tubule. Of the reabsorbed urate, 45% to 50% 
is then secreted in the S1 and S2 segments of the proximal 
tubule. Much of the secreted urate is again reabsorbed in the 
S3 segment of the proximal tubule.85 Most persons who are 
hyperuricemic never get gout, but the risk of gout goes up 
dramatically with higher serum uric acid levels. In one large 
study, the 5-year risk of gout varied from 0.6% for those with 
a serum uric acid level of 7 mg/dL to 30.5% for those with 
a level of 10 mg/dL or higher.28
In recent years a family of organic anion transporter 
proteins has been discovered. Enomoto and colleagues 
cloned one called urate transporter 1 (URAT-1) which is 
highly specific for urate transport.88 URAT-1 is present in 
the proximal tubular epithelial cells89 and exchanges urate 
with other endogenous organic anions as well as drug anions. 
Most uricosuric drugs are thought to act by suppressing the 
activity of URAT-1, including probenecid, benzbromarone, 
sulfinpyrazone and losartan. In the case of probenecid at least, 
there may also be an ATP-inhibiting effect via pannexin-1.90 
Aspirin may also affect uric acid excretion in part through 
a mechanism involving URAT-1. URAT-1 is thought to be 
critically important in maintaining serum uric acid levels. 
Individuals with nonfunctional mutations of URAT-1 have 
very low uric acid levels.89,91 The clinically relevant biology 
of URAT-1 has recently been reviewed.92
UAT-1 is another renal urate transporter that has subse-
quently been identified as galectin-9.93 Its role in intestinal 
and renal secretion of urate anion has yet to be established. 
A number of other urate transporters have been discovered, 
and seem especially important in hereditary gout.94–97
Patients with familial juvenile hyperuricemic nephropa-
thy (FJHN) have early onset of hyperuricemia, hypertension, 
progressive renal failure and variable degrees of gout. Most 
cases are due to a mutation in the UMOD gene which encodes 
uromodulin (Tamm-Horsfall glycoprotein).85,98 Uromodulin 
is hypothesized to be important for the structural integrity 
of the ascending loop of Henle. Although phenotypically 
distinct from FJHN, some forms of medullary cystic kidney 
disease, type 2 and glomerulocystic kidney disease are also 
thought to be attributable to mutations in UMOD and have 
hyperuricemia associated with them.85,99International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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Inflammation in gout – recent discoveries
The discovery of elevated serum uric acid levels in gouty 
patients is normally credited to Garrod in 1859.100 It was 
not until 1962 that the inflammatory nature of MSU, the 
insoluble, crystalline salt of uric acid that typically forms 
tophi, was proven. In that year Faires and McCarty injected 
their own knees (and those of their fellows) with MSU, 
proving that minute quantities of crystals can cause severe 
inflammation.101 Yet, it is well known that between attacks in 
up to 70% of gouty patients, MSU crystals can be found float-
ing free in synovial fluid without inciting inflammation.102 
Clearly other factors besides the simple presence of crystals 
are at work to turn on/off the inflammatory cascade.
Triggering of inflammation by crystals
The predilection of gout for the first metatarsophalangeal 
joint (MTP) has been hypothesized to represent the result of 
a number of factors.103 It is hypothesized that a small joint 
effusion forms during daytime activities, particularly activi-
ties that are more strenuous or traumatic to the joint (the first 
MTP is a frequent site of minor trauma and hence, osteoar-
thritis). At night (when most gout attacks occur) tissue edema 
fluid (more abundant more distally in the lower extremity) is 
gradually reabsorbed into the circulation. The concentration 
of urate rises in the joint because urate is reabsorbed more 
slowly than water. The lower temperature of the distal foot 
is thought to also contribute to precipitation of MSU crystals. 
The net result is the classic but unwelcome nocturnal visitor 
that so rudely awakens the victim from a sound sleep.
For a gout attack to occur, there must be deposition of 
MSU in the tissues and there must also be the triggering of 
inflammation. Crystals alone are not enough, as evidenced by 
the fact that tophi only occasionally become inflamed, and also 
that MSU crystals can often be found floating freely in syn-
ovial fluid from uninflamed joints. A number of factors have 
been discovered in recent years that control the inflammatory 
process, and there are several eloquent reviews.1,85,104–108
Liberation of free crystals is one factor that can trigger the 
acute gout attack. Free crystals can be newly deposited, or may 
form through dissolution of tophi (as when instituting treat-
ment with a hypouricemic agent) or may be dislodged from 
otherwise stable deposits by trauma.109 It is estimated that only 
approximately 20% of persons with sustained hyperuricemia 
actually develop gout.28 A rapid decline in serum uric acid 
level can precipitate an attack. This often occurs at the start 
of hypouricemic therapy or more characteristically when an 
alcoholic suddenly ceases to imbibe ethanol for any reason.
Although not as novel as the developments reported in 
the following, protein-coating of crystals has been shown in 
the past to affect inflammation. Coating with IgG, comple-
ment fragments or fibronectin are pro-inflammatory in this 
regard, while coating with lipoproteins B and E reduces the 
inflammatory reaction to the crystals.108,110,111
Cytokines
Much remains to be learned about the process of crystal-
induced inflammation, but there have been some advances 
in recent years, and there are several recent reviews.108,112 
Crystals of MSU or calcium pyrophosphate dihydrate 
(CPPD) trigger intense neutrophilic influx into joints in just 
1 to 2 hours.101,113 In addition to neutrophils, other cell types 
are also capable of phagocytizing crystals including mono-
cytes and endothelial cells.114–116 Recent studies by Martin 
and colleagues suggest that resident macrophages (rather 
than recruited neutrophils and monocytes) actually initiate 
and drive the inflammatory response,117,118 while eventual 
differentiation of monocytes into macrophages results in 
resolution of crystal-induced inflammation.
Research over the past 20 years has demonstrated central 
roles for the cytokines IL-1β, IL-6, tumor necrosis factor-α 
(TNF-α) and IL-8.118 IL-1 seems to be particularly important 
since IL-1 inhibitors can abort crystal-induced inflammation 
both in vitro and in the clinic.
As reviewed by Liu-Bryan and Rose,108 neutrophils 
move into joints by the actions of IL-1 and TNF-α.104,119 
This stimulates upregulation of E-selectin and chemotactic 
factors CXCL8 and CXCR2. Phagocytosis of crystals by 
neutrophils then causes release of cytoplasmic mediators 
such as calgranulins.120
MSU crystals can activate several inflammatory path-
ways directly. MSU crystals are rapidly phagocytized by 
neutrophils in vitro and in vivo. They stimulate monocytes 
to express large quantities of IL-1β (via formation of the 
NALP-3 inflammasome complexes).104,121,122 Uric acid has 
been included among the “endogenous alarmins”.123
One of the primary mediators of urate-induced inflam-
mation is IL-1β.124,125 Interestingly, IL-1β production by 
mononuclear cells is triggered by MSU but not by CPPD or 
hydroxyapatite,124,126 suggesting that crystal-induced inflamma-
tion can be triggered by other pathways as well. Nevertheless, 
the formation of IL-1 is a clinically important process that can 
be blocked by IL-1 inhibitors to great therapeutic advantage.
Inflammasomes
The term “inflammasome” first appeared in the medical lit-
erature in 2002.127 Martinon and colleagues described it as a 
  caspase-activating complex that includes caspase-1, caspase-5, 
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sharing structural homology with NODs (NALP = NACHT 
domain, leucine-rich repeat domain, and pyrin domain).
Inflammasomes are large intracellular assemblies of 
several types of proteins that trigger or facilitate the inflam-
matory process.122,128,129 Inflammasomes are an important 
intracellular mediator in the production of IL-1β and IL-18 
and may also induce cellular pyroptosis, a type of programmed 
cell death distinct from apoptosis.130 IL-1β is activated by 
intracellular cleavage of Pro-IL-1 by caspase-1. Caspase-1 in 
turn is thought to be activated by the NALP-3 inflammasome. 
Mutations in the NALP-3 inflammasome may lead to IL-1β 
overproduction, as in familial Mediterranean fever. There 
have been several thorough reviews on the role of inflam-
masomes in gout and in other auto-inflammatory conditions, 
particularly the cryopyrinopathies such as familial cold-
induced urticaria, Muckle–Wells syndrome and CINCA 
syndrome (chronic infantile neurologic, cutaneous, articular 
syndrome).122,131–134
Toll-like receptors
Toll-like receptors (TLRs) are membrane-bound extracel-
lular receptors that constitute an important part of the innate 
immune system. Their primary function is to recognize 
microbial invaders.122 NOD-like receptors are intracellular 
complexes that sense microbial and nonmicrobial danger 
signals (such as crystals) and then form inflammasomes.
There is some understanding of how IL-1 production is trig-
gered. The innate immune system in the form of TLRs appears 
to be involved,119,135–137 especially TLR-2 and TLR-4 which 
have been shown to be activated by MSU crystals.104,135 Using 
a mouse model and protein-free, endotoxin-free MSU crystals, 
it was found that deficiency of TLR-2 and/or TLR-4 resulted 
in blunted production IL-1β, TNF-α and other cytokines.119 
While TLRs appear to have a role in the amplification of the 
inflammatory response, there is also some evidence from 
murine models that they are not actually required.118
CD14 is a pattern recognition receptor on the surface of 
phagocytic cells that seems to be important for crystal-induced 
IL-1 production. Scott and colleagues found that MSU crystals 
but not latex beads, diamond crystals or aluminum triggered   
CD14 activation. CD14 deficient cells were still able to phago-
cytize crystals but expressed approximately 90% less IL-1.137 
There is some evidence from murine models that TLRs do not 
bind MSU directly, but rather that CD14 binds to the crystals, 
making the crystals recognizable by TLRs.118,137
Resolution of the gout attack
Gout attacks eventually resolve, even without specific 
treatment. If little is known about how crystals initiate 
inflammation, less is known about the mechanisms leading 
to spontaneous resolution of gout. As monocytes differentiate 
into macrophages they appear to lose the ability to secrete 
inflammatory cytokines in response to MSU crystals. Yagnik 
and colleagues recently showed that such differentiated 
macrophages also secrete anti-inflammatory cytokines, 
particularly TGF-β1.138 Other anti-inflammatory mediators 
such as IL-10, PGD2 and 15deoxy-PGJ2 (ligand of PPARγ) 
are also secreted mainly by macrophages.108,138,139
Resolution of gout follows the normal 3-phase pattern 
found in the body, including removal and/or neutralization 
of crystals, clearance of apoptotic cells and debris, and a 
switch of cytokine patterns from the pro-inflammatory to 
anti-inflammatory.108 Superoxide seems to help break down 
MSU crystals but not CPPD crystals.140
Although it is often said that crystals (mostly extracel-
lular but occasionally intracellular as well) may be found in 
joints between attacks, it is important to realize that low-level 
inflammation persists along with the potential for ongoing 
joint damage.141
Notes on clinical gout
Nearly every physician is familiar with the acute, nocturnal, 
monoarticular presentation of gout in the first MTP joint 
that awakens the sufferer from sound sleep. Some notes on 
the less common clinical features of gout may be helpful. 
There are 4 stages in the development of clinical gout:142 
asymptomatic hyperuricemia, the gouty attack (usually 
monoarticular, at least at first), the intercritical period and 
chronic gouty arthritis. In most persons, hyperuricemia 
exists for many years before the first clinical attack of gout. 
While the first clinical attack is usually monoarticular, it 
could also be polyarticular. The first MTP joint is the first 
joint attacked in roughly 50% of individuals. Some persons 
never have clinical attacks of gout, but rather they slowly 
build tophaceous deposits in and around joints. One charac-
teristic presentation is acute inflammation of 1 or more finger 
joints, particularly Heberden’s nodes in elderly females with 
osteoarthritis who are using diuretics.143,144
Attacks before the age of 25 to 30 years in men (or 
at any time any premenopausal woman) should raise the 
suspicion of an inborn enzyme defect or one of several 
hereditary kidney diseases. The latter include familial 
juvenile hyperuricemic nephropathy, autosomal dominant 
medullary cystic kidney disease and autosomal dominant 
polycystic kidney disease.46
Pain is the last symptom to appear and the first to disap-
pear. A corollary of this is that relatively painless swelling 
of a joint or a digit may persist for weeks. This often gives International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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rise to a fear of osteomyelitis, occasionally resulting in 
unnecessary surgery to debride an “infected” digit. Gout is a 
common cause of dactylitis in adults. Other common causes 
include psoriatic arthritis, sarcoidosis, osteomyelitis and, in 
children, sickle-cell disease. The affected digit may even take 
on a dusky, reddish purple hue as the inflammation becomes 
chronic. If the attack persists untreated, and if inflammation 
has been severe, desquamation tends to occur. Dactylitis can 
take 1 or 2 months to resolve.142
Unfortunately, attacks tend to become more frequent 
and more severe with time with a tendency to involve more 
joints.
The intercritical period begins after resolution of the first 
gout attack. During this stage, joints appear to return to normal. 
During this stage, ultrasound or magnetic resonance imaging 
(MRI) may still show tophaceous deposits around affected 
joints. Untreated, such deposits tend to worsen with time.
The stage of chronic tophaceous gout occurs when mono-
sodium urate builds up around tissues so as to be clinically 
obvious between attacks. The word “tophus” is derived from 
the Greek word for chalk. Tophi may be quite firm and may 
be confused with tumors. Tophi mimic rheumatoid nodules, 
particularly in men where they tend to occur along the olecra-
non aspect of the forearm. Tophi can form over an interval 
of only a few days in persons with severe hyperuricemia, 
such as occurs with critical illness hyperuricemia.142,145 
Occasionally, spontaneous rupture occurs. The white, pasty 
material that exudes is almost pure MSU, sometimes with 
ultramicroscopic calcium crystals, but only rarely white cells. 
Untreated, draining tophi can take months or years to close. 
Detailed descriptions of the osseous and the dermatologic 
manifestations of gout have been published.142
Tophaceous material is a white pasty substance that is 
easily identified microscopically as sheets of needle-shaped 
crystals. MSU crystals are somewhat soluble in water and 
formaldehyde. Pure alcohol fixation is necessary to preserve 
the crystals in tissue samples.146,147
Role of diagnostic imaging
Definitive diagnosis of gout (including differentiation from 
pseudogout and the ever-lurking specter of septic arthritis) 
has traditionally required arthrocentesis. Until recently, imag-
ing has not been particularly helpful. The subject of imaging 
has been recently reviewed.148,149
Traditional radiographs are largely unhelpful in the diag-
nosis of gout since the crystals are relatively radiolucent, 
and bony changes do not occur until late in the course of the 
disease. Radiographs are helpful to look for chondrocalcinosis 
which would lead to a diagnosis of pseudogout instead. 
Late destructive changes of gout that may be apparent on 
radiographs include overhanging edges, erosions and cysts 
within bone. The presence of overhanging edges helps dis-
tinguish gout from rheumatoid arthritis. Also helpful is the 
tendency of bony erosions and cysts in gout to have sclerotic 
margins, and there is usually absence of joint space narrowing 
and there is lack of periarticular demineralization.
Imaging of gout in the US took a leap forward in the past 
10 years with the popularization of musculoskeletal ultrasound, 
which has been used for many years in Europe.150 Ultrasound 
offers the ability to diagnose gout between attacks (when there 
is little or no aspiratable fluid in joints) or in patients who may 
have asymptomatic hyperuricemia. Ultrasound may also allow 
diagnosis of palpable tophaceous deposits without needle 
aspiration, and may allow differentiation between gout and 
pseudogout based on the location and characteristics of the 
crystal deposits.151 Gouty joints often show the characteristic 
“double contour sign” on ultrasonographic imaging.152 We find 
ultrasound to be particularly helpful in the long-term man-
agement of gout by following the dissolution of tophaceous 
deposits over time and using this information to adjust the 
intensity of hypouricemic treatment.
The main drawback of ultrasound is the need for 
somewhat extensive training and practice. It is also not yet 
universally available in the US. Most radiologists and rheu-
matologists in the US do not receive significant training in 
the musculoskeletal application of ultrasound.
Magnetic resonance imaging and computed tomography 
have also been used to diagnose gout, particularly topha-
ceous deposits. MRI is particularly helpful in detecting bony 
changes that are not visible on plain radiographs.153,154 One 
caveat is that the magnetic resonance appearance may mimic 
osteomyelitis particularly during the acute attack when there 
may be intraosseous edema and also soft tissue inflammation. 
We have seen 2 patients operated for lumbar osteomyelitis 
who in reality had acute gout of the facet joints that improved 
rapidly with corticosteroid treatment.
Treatment of the acute attack
The treatment of gout is traditionally divided into 3 phases: 
1) treatment of the acute attack; 2) prevention of future 
attacks; and 3) hypouricemic therapy. We will consider each 
separately.
Inappropriate treatment of acute gout seems to persist. 
One recent study found that of 159 patients who consulted a 
physician for their gout, 10 received definitely inappropriate 
treatment and 43 received potentially inappropriate treatment International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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for their recurrent attacks. Inappropriate treatment was 
defined as use of a hypouricemic agent to treat an acute attack, 
without having used it prophylactically previously.155
Nonsteroidal anti-inflammatory agents
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the 
drugs of choice for the average patient with gout without 
comorbidities. They are usually not an option in persons 
with chronic renal disease as they can worsen renal function 
temporarily or permanently, cause fluid retention and increase 
blood pressure, occasionally dramatically. This holds true to 
both traditional NSAIDS such as indomethacin as well as 
COX-2 inhibitors such as celecoxib, although the latter seems 
to be much more benign in this regard than the related drug 
rofecoxib, which was withdrawn from the market in the US.
Colchicine
Colchicine is perceived as safer than NSAIDs in patients 
with mild to moderate renal insufficiency, as long as the 
maintenance dose is adjusted. Colchicine is an alkaloid 
derived from Colchicum autumnale, the autumn crocus, a 
species that is more properly placed in the lily family. Plant 
extracts containing colchicine have been used to treat gout 
for more than 2000 years. The oral form of colchicine has 
been available for gout treatment for 70 years. However there 
has been no FDA-approved preparation until recently and 
the branded product is being marketed under the name of 
Colcrys®; URL Pharma, Inc.).
The Colcrys® trial showed that a low-dose regimen of 
colchicine (1.8 mg total over 1 hour) and a high-dose regimen 
(4.8 mg total over 6 hours) were equivalent in aborting the 
acute gout attack at 24 hours, with many fewer adverse events 
in the low-dose group. Additionally, formal recommendations 
for using colchicine in patients with renal insufficiency and 
hepatic insufficiency were made, and the many drug interac-
tions of colchicine were formalized.156
Colchicine is a drug with both a narrow therapeutic-
  toxicity window and a marked variability between individuals 
in drug disposition. Often, the cumulative dose that relieves 
the gout attack is close to the dose that causes diarrhea, 
abdominal cramping and nausea. Dose reduction is commonly 
recommended in patients with a creatinine clearance of less 
than 50 mL/min. Because the Colcrys® regimen is itself low-
dose, dosage adjustment is not necessary in the presence of 
mild-to-moderate renal insufficiency, according to the official 
prescribing information.157 In severe renal insufficiency, the 
dosing for acute flares is unchanged (1.8 mg/24 hours) but it 
should not be repeated more frequently than every 2 weeks. 
The prophylactic dose should be reduced to 0.3 mg/day. 
In patients receiving dialysis, the dose for gout flares is 
reduced to 0.6 mg × 1 dose only, to be repeated in not less than 
2 weeks. The prophylactic dose is reduced to 0.3 mg twice a 
week “with close monitoring”.157 Colchicine is not removed 
by dialysis or exchange transfusion.158 The manufacturer does 
state that Colcrys® is contraindicated in patients with severe 
renal impairment who are also receiving drugs that inhibit 
permeability glycoprotein (P-glycoprotein, P-gp; also known 
as ABCB1) or that inhibit CYP3A4. P-gp is an important 
transporter protein in the elimination of colchicine.
Colchicine undergoes metabolism by the liver primarily 
through deacetylation. Approximately 20% of the parent 
drug is excreted unchanged in the urine; in the face of hepatic 
dysfunction, this percentage increases.
Serious colchicine toxicity includes severe diarrhea 
leading to dehydration and metabolic acidosis, bone 
marrow failure, polyneuropathy, chronic myopathy and 
rhabdomyolysis. Risk factors for toxicity include older age, 
concomitant use of CYP3A4 inhibitors (such as cimetidine, 
erythromycin, clarithromycin, diltiazem, verapamil, and 
HMG-CoA reductase inhibitors), inhibitors of P-gp (such as 
cyclosporine), and most consistently, renal impairment.
Cyclosporine potentiates colchicine neuromyopathy as 
does renal insufficiency which itself may be induced by 
cyclosporine, compounding the problem. Neuromyopathy 
may occur within weeks of starting the combination. Notably, 
cyclosporine delayed colchicine-induced diarrhea in an 
animal model system, likely due to modulation of intestinal 
P-gp.159 Hence, it is suspected that cyclosporine could mask 
the gastrointestinal side effects of colchicine that customarily 
signal the onset of acute toxicity. Myopathy and neuropathy 
are often reversible upon discontinuation of the medication 
within 2 to 12 weeks.160,161
In 2008 the FDA withdrew marketing approval for all 
existing intravenous preparations of colchicine secondary to 
inappropriate use and high mortality associated with its use.
Intra-articular and systemic 
corticosteroids
Intra-articular corticosteroids are particularly helpful in 
acute gout. Injected joints are usually markedly improved 
in 24 hours. In our experience, intra-articular corticosteroids 
provide the fastest resolution of the acute gouty flare. Intra-
articular steroids are also very safe in patients with renal 
insufficiency and should perhaps be a treatment of first choice 
unless there is polyarticular gout. When properly performed, 
arthrocentesis should not be particularly uncomfortable, International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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even with an inflamed joint. Lack of operator experience is 
probably the main impediment to more widespread use of 
intra-articular corticosteroids.
Intra-articular corticosteroids may not be feasible when 
many joints are affected. Systemic corticosteroids are a 
better option in such cases. Prednisone in a dose of 30 mg 
twice daily is effective in most cases. Because of the short 
half-life of prednisone, once daily dosing is often ineffective. 
Oral corticosteroids are well absorbed and are generally as 
effective as intravenous steroids. Corticosteroids are tapered 
over 7 to 10 days. It is important to begin a prophylactic agent 
such as colchicine when tapering corticosteroids to avoid a 
rebound flare of gout activity.
Biologicals
There is some anecdotal evidence for the effectiveness of 
TNF-α blocking agents for the management of severe gout.162,163 
Conceptually this makes some sense, since crystals are a potent 
stimulus for TNF-α production by mononuclear cells.164,165 
Controlled trials in gouty subjects are lacking to date.
In one report the IL-1 receptor antagonist anakinra 
(Kineret®; Biovitrum AB) was reported to be rapidly effective 
in suppressing flares in 10 patients with difficult-to-treat 
acute gout.166 Anecdotally, inhibition of IL-1 may be a more 
effective strategy for treating acute gout than inhibition of 
TNF-α.167,168 There are some patients with severe gouty flares 
who cannot or should not receive NSAIDs, colchicine or high-
dose corticosteroids, or who are refractory to such treatments. 
In such cases, anakinra is sometimes an alternative although it 
is not FDA-approved for treatment of gout. While expensive if 
used chronically for rheumatoid arthritis (for which the drug is 
approved), at a cost of US$75 per day it is actually quite cost-
effective when given for 3 to 5 days to hospitalized patients who 
otherwise might require high-dose intravenous corticosteroids 
with treatment of resulting steroid complications.
On the horizon
Rilonacept (Arcalyst®; Regeneron Pharmaceuticals, Inc.) is 
a dimeric fusion protein that acts as an IL-1 inhibitor that is 
FDA-approved for treatment of cryopyrin-associated periodic 
fever syndromes. Its effectiveness in chronic tophaceous 
gout was assessed in a pilot study. While it did not reduce 
the number of affected joints, it did decrease the severity of 
symptoms in affected joints. It also decreased C-reactive 
protein (CRP) levels initially but CRP trended upward as 
treatment continued beyond 6 weeks.169
Canakinumab is an investigational fully humanized 
monoclonal antibody directed against IL-1β. In a Phase II 
study involving 191 subjects with acute, difficult-to-treat 
gout, single doses of canakinumab were more effective 
beginning at 24 hours than triamcinolone acetonide 40 mg 
intramuscularly. It also effectively prevented recurrences 
for up to 8 weeks.170 Canakinumab (Ilaris®; Novartis 
Pharmaceuticals) is currently FDA-approved and available on 
the US market for treatment of cryopyrin-associated periodic 
fever syndromes including familial cold autoinflammatory 
syndrome and Muckle–Wells syndrome.
Biological treatment/prophylaxis of gout attacks is still 
in its infancy. There are many questions to be addressed 
before biological treatment can be generally recommended. 
Among the issues to be resolved are the very high cost, as 
yet unproven efficacy and unclear safety profile compared 
with traditional agents.
Tranilast is an interesting investigational compound 
(it is on the market in parts of Asia) with anti-inflammatory, 
antifibrotic and uricosuric effects. It is currently in trials for 
gout, hyperuricemia and other conditions. It has the potential 
to act as both a suppressor of acute attacks and possibly a 
hypouricemic therapy as well.171
Apremilast is a novel phosphodiesterase 4 (PDE 4) 
inhibitor with potent anti-inflammatory properties which 
is currently being studied as a treatment for acute gout 
attacks.172,173 As with tranilast, it has the potential to prevent 
acute flares in those who may not be able to use NSAIDs.
Attack prophylaxis
Once the acute attack has subsided, the next goal is preven-
tion of future attacks.142 This is particularly important in 
the first few weeks after an acute attack. Generally, either 
an NSAID or colchicine is used for this purpose. NSAIDs 
are the treatment of choice in persons with concomitant 
osteoarthritis. For prophylaxis, lower doses usually suffice, 
such as celecoxib 200 mg daily or naproxen 375 mg/day. 
Indomethacin is not recommended for this use, particularly 
in persons who are taking triamterene, in whom it can cause 
acute renal failure.174,175 Colchicine prophylaxis is used in 
persons who cannot or should not take NSAIDs. As described 
above, the dose of colchicine must be reduced in the presence 
of renal or hepatic insufficiency. Chronic colchicine toxicity 
takes the form not of diarrhea, but rather of myoneuropathy 
which combines symptoms of peripheral neuropathy with 
muscle weakness and usually mildly elevated creatine 
kinase.161,176–178 Unfortunately, a few individuals cannot take 
even 0.3 mg/day of colchicine without severe diarrhea. This 
appears to be idiosyncratic. Prophylaxis remains a major 
problem in these individuals. Rarely, we have used low-dose International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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daily corticosteroid treatment as a preventive when there 
has been no other choice, but our impression is that tachy-
phylaxis develops fairly rapidly to the preventive effect and 
dosage escalation is required, with all of the attendant side 
effects and risks that accompany chronic corticosteroid use. 
IL-1 inhibitors offer an effective if expensive alternative. As 
noted above, 2 such agents are currently available on the US 
market but are not FDA-approved for use in gout.
The duration of prophylaxis varies. In a person with-
out obvious tophaceous deposits who has only occasional 
attacks, prophylaxis may be necessary for only 2 or 3 weeks. 
Prophylaxis is generally used for several months in those 
who are also beginning a hypouricemic agent, because more 
frequent attacks may accompany sudden lowering of uric 
acid levels.142,179 Generally, the more potent the hypouricemic 
effect, the more frequent and the more severe are the gout 
flares during the initial months of hypouricemic treatment. 
In persons with tophi, prophylaxis should be continued until 
all tophaceous deposits have been dissolved. Perhaps the best 
way to follow the need for gout attack prophylaxis is with 
the use of musculoskeletal ultrasound to determine when all 
tophaceous material has been dissolved away.151–154,180,181
Hypouricemic therapy
Introduction
Moderation of alcohol consumption, diets tailored to control 
portion sizes, maintenance of ideal body weight and reducing 
insulin resistance34 are lifestyle changes that are recommended 
in contrast to use of an unpalatable low purine diet. Specific 
foods that seem to decrease uric acid levels include dairy 
products, coffee and vitamin C. Increased levels are associ-
ated with red meat, fructose (sweetened beverages) and beer. 
Unfortunately, the maximum serum urate reduction achieved 
by diet alone is typically only ∼1 mg/dL or up to 15% (unless 
accompanied by significant weight reduction), which makes 
pharmacologic options necessary for most patients with gout. 
The role of diet has recently been reviewed.182,183
Role of diet
Over the past 20 years, the average weight of American men 
has increased from 168 pounds (76 kg) to approximately 
180 pounds (82 kg), and women from 142 pounds (64 kg) 
to 152 pounds (69 kg).184 According to the National Institute 
of Diabetes and Digestive and Kidney Diseases (NIDDK), 
about two-thirds of Americans are overweight (BMI $ 25) 
and nearly one-third are obese (BMI $ 30).185 The proportion 
of obese persons increased from 13.3% to 32.1% since 1960. 
In addition to gout, overweight and obesity are associated 
with type II diabetes, coronary artery disease, hypertension, 
stroke, hyperlipidemia, gallbladder disease, degenera-
tive joint disease, sleep apnea and several types of cancer 
(including breast, colorectal, endometrial and kidney). Choi 
and colleagues found that the relative risk of gout was 1.95 
for men with a BMI of 25 to 29.3 and 2.33 for men whose 
BMI was 30 to 34.9 and 2.97 for a BMI of $35, compared 
with men whose BMI was 21 to 22.9.186 In summary, the 
major contribution of food to gout, at least in the current 
world epidemic, appears to be simply too much.
Perhaps surprisingly, there is a strong correlation between 
intake of sugar-containing soft drinks and serum uric acid 
levels. After adjusting for other variables such as body weight, 
Choi and colleagues found that those consuming four or more 
servings per day had uric acid levels on average 0.42 mg/dL 
higher than those with no intake of sweetened soft drinks, 
and the risk of hyperuricemia was increased 1.8-fold.187 
In another study looking at males alone, the association was 
even stronger.188 Unfortunately there was also an associa-
tion with consumption of fructose-containing fruits such as 
apples and oranges. (One could be forgiven for thinking that 
consumption of an apple a day is somehow healthier than 
drinking a pint of fruit juice.) Interestingly, consumption 
of cherries and vegetable protein has been associated with 
decreased risk.189 Schlesinger notes that an acute purine 
load can raise serum uric acid level by 1 to 2 mg/dL within 
24 hours, sufficient to account for gout attacks occurring 
after dietary indiscretions on holidays.189
Patients often ask what they can do to improve their gout, 
although enthusiasm is often dampened by the recommendation 
to lose weight and to reduce alcohol consumption. Furthermore, 
although weight loss ultimately helps, fasting or near fasting can 
actually provoke gout attacks, presumably due to ketosis.190
When it comes to gout (in contrast to the situation with 
driving under the influence) all alcohol may not be equivalent. 
Beer (which has high purine content) seems to raise uric acid 
levels more per ounce of alcohol ingested and seems to be 
associated with a higher risk of gout than distilled spirits.191 
Modest intake of wine (1 or 2 glasses per day) was not sig-
nificantly associated with increased risk of gout.
Cherry juice
Many patients have heard that cherry juice is good for gout. 
But is it? A number of websites that offer cherry products 
for sale assure us that it is. A PubMed search combining 
gout with permutations of the word cherry turned up exactly 
2 interventional trials. In one study, plasma urate levels 
declined 14.5% 5 hours following ingestion of 280 g of red International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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Bing cherries following an overnight fast. Other fruits were 
not effective. The subjects of the study were 10 healthy 
premenopausal women of normal weight with a normal 
mean plasma urate level.192 A trial of cherry juice in mara-
thon runners showed a 2 to 3 mg/dL lower uric acid level 
post-race compared with placebo, but in that particular trial 
it was unclear if cherry juice enhanced uric acid excretion 
or decreased uric acid production.193 The baseline uric acid 
level was also slightly lower in the cherry juice group. Both 
a hypouricemic effect and an anti-inflammatory effect have 
been attributed to cherry juice.193,194
The hypouricemic effect of cherries may not be attributable 
to the vitamin C content. While acerola cherries are very high 
in vitamin C (4700 mg/280 g), most American varieties contain 
much less (19.6 mg/280 g for sweet cherries, 28 mg/280 g for 
tart cherries).195 One cup of raw cherries (with pits) weighs 
140 g (sweet) or 155 g (tart).195 A study done in 1950 of 12 gout 
patients suggested that 0.5 pound (0.2 kg) of cherries (several 
varieties were effective) or an equivalent amount of cherry 
juice prevented gout attacks.196 The mechanism of action is 
unclear. It is unfortunate that there is a dearth of data about such 
a wholesome and good-tasting potential remedy for gout.
vitamin C
Does vitamin C reduce uric acid levels? In one small study, 
4 g caused a uricosuric effect within a few hours. A few 
subjects took 8 g/day and were noted to have reduced serum 
uric acid by 1.2 to 3.1 g/dL.197 A later prospective cohort 
study found that each 500 mg increase in vitamin C intake 
was associated with a multivariate relative risk of 0.83 for 
gout compared with those who took no supplement.198 This 
subject was also reviewed by Gao and colleagues.199
Pharmacological urate-lowering 
strategies
Hypourecemic therapy should be considered for most gouty 
patients, including those with end stage renal disease and 
nephrolithiasis. The main reason to use hypourecemic treat-
ment is to prevent long-term complications of gout such as 
urate nephropathy, urate kidney stones, development of tophi 
and joint damage. Once the patient has suffered 1 attack of 
acute gout, the likelihood of recurrent attacks is extremely 
high. In patients not treated with urate-lowering drugs, 62% 
will experience a recurrence within 1 year of the initial attack, 
78% by 2 years, and 89% by 5 years.200 For patient comfort, 
it is important to reduce or eliminate gouty flares. Thus, 
once urate-lowering medication is begun, the treatment is 
not intermittent; it is continuous and lifelong.
Uric acid level should be maintained below the solubility 
concentration of 6.8 mg/dL, preferably below 6.0 mg/dL. 
Still, some patients may continue to have clinically important 
deposits of MSU and/or attacks. Hypourecemic agents should 
not be started during the acute attack as that can exacerbate 
a flare. We recommend that patients who experience acute 
attacks while taking a hypourecemic agent do not discontinue 
the agent because the subsequent increase in serum uric acid 
level may worsen the attack.
On the other hand, hypourecemic therapy may not be nec-
essary for patients with a frequency of gout attacks less then 2 
or 3 times per year, who have no tophaceous deposits, and who 
have mildly elevated uric acid levels that may be amenable 
to lifestyle changes and nonpharmacological treatment (see 
above). Hypouricemic treatment may not be indicated in very 
elderly patients who may not require long-term prophylaxis 
against renal or joint damage. Such patients may do very well 
simply with colchicine prophylaxis against acute attacks.
Allopurinol and febuxostat (but not probenecid) both 
provide effective prophylaxis against nephrolithiasis in most 
gouty patients.
Allopurinol
Allopurinol has been the cornerstone of urate-lowering 
treatment in the US since 1966, but despite potent xanthine 
oxidase inhibition and urate-lowering properties, allopurinol 
is commonly underdosed or poorly adhered to in long-term 
treatment.201–203
In patients with normal renal and liver function, allopurinol 
is generally started in a dose of 100 mg/day and increased by 
100 mg/day weekly until 300 mg/day is being taken. The goal 
is to maintain a serum uric acid level 6.0 mg/dL. The dose 
may be gradually increased to 800 mg/day in patients with 
normal renal function, but the risk of serious idiosyncratic 
toxicity increases at higher doses, and with renal insuffi-
ciency (see below). Despite the wide dose range over which 
allopurinol is approved in the US, only a single randomized 
controlled trial has evaluated the efficacy and safety of 
allopurinol in doses exceeding 300 mg/day.204
The most common adverse effects are gastrointestinal 
upset and rash. The incidence of rash is estimated at ∼2%.205,206 
Unfortunately, serious toxicity is completely unpredictable 
and is considered to be allergic in nature. Allopurinol-induced 
rash usually resolves upon discontinuation of the drug, but 
rechallenge may lead to life-threatening toxic epidermal 
necrolysis. In the past, persons who required allopurinol 
could sometimes successfully undergo desensitization,207 but 
this is less commonly done since febuxostat has provided an International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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alternative for allopurinol-allergic patients. The occurrence 
of xanthine urinary calculi is a theoretical possibility under 
low urinary flow conditions.
One rare but exceedingly important reaction to allopurinol 
is the allopurinol hypersensitivity syndrome (AHS), which 
consists of rash (sometimes severe as in toxic epidermal 
necrolysis or exfoliative dermatitis), eosinophilia, leukocyto-
sis, fever, hepatitis and progressive renal failure (usually due 
to interstitial nephritis).206 One particularly alarming feature 
of the syndrome is that it often is relentlessly progressive (and 
fatal) despite discontinuation of allopurinol and institution of 
corticosteroid therapy.208,209 There are no published trials or 
case reports that examined immunosuppressive treatments. 
The incidence of AHS is estimated at ∼0.1%.205 Allopurinol 
is one of the more commonly used drugs that can cause 
severe hypersensitivity reactions.210 Risk factors for AHS 
include higher dose, renal insufficiency, diuretic use and 
higher oxypurinol concentrations.211 There may also be a 
genetic predisposition. HLA-B*501 was found in 100% of 
51 Taiwanese patients with severe cutaneous reactions to 
allopurinol, but in only 20% of the general population. 212
According to the allopurinol prescribing information,213 
the frequency of hypersensitivity reactions may be increased 
in patients with decreased renal function who are receiving 
thiazides concurrently. It is also stated in the package insert 
that patients with decreased renal function require lower 
doses. “Therefore, a dose of 100 mg/day or 300 mg twice a 
week or perhaps less may be sufficient ...” With a creatinine 
clearance of 10 to 20 mL/min, a dose of 200 mg “is suitable”, 
and for creatinine clearance between 3 and 10 mL/min, the 
dose “should not exceed 100 mg”.
Allopurinol dosing in the presence of renal insufficiency 
has recently been reviewed.205,214,215 The main concern has been 
accumulation of the major metabolite oxypurinol which has 
a half-life of 18 to 30 hours in the presence of normal renal 
function, increasing up to a week in those with severely impaired 
renal function.205,216 Unfortunately reductions in serum uric acid 
level do not correlate well with oxypurinol concentrations, 
hence some persons are resistant to the urate-lowering effects 
even at very high serum levels of oxypurinol.
Recommendations for lower doses of allopurinol in the 
presence of renal insufficiency stem mainly from reports that 
most patients with AHS had pre-existing renal insufficiency 
and were receiving full doses of allopurinol.209,217,218 Critics 
point out that the relationship between oxypurinol concen-
trations and AHS remains unproven,219,220 and that no study 
has systematically demonstrated that dosage reduction in 
renal insufficiency reduces the risk of severe AHS. Some 
studies have found no relationship of AHS with dose in renal 
insufficiency.212,219,220 In other words, it is suggested that the 
renal insufficiency itself confers the risk, not the dose of 
allopurinol.219 Lastly, the increased risk of AHS (if any) must 
be balanced against the risk of inadequate control of gout that 
often follows from using the lower recommended doses.
The frequency of gouty attacks seems to decline once 
CKD patients are placed on dialysis.221,222 Nevertheless, when 
allopurinol is required by patients undergoing dialysis, it may 
be started at 100 mg every other day, to be administered post-
dialysis. If dialysis is performed daily, then an additional 50% 
may be required post-dialysis.205 Interestingly, the package 
insert makes no mention of dialysis.213 It is noteworthy that the 
phosphate binder sevelamer has been reported to have a modest 
urate-lowering effect and may be useful as an adjunct.205,223
Unfortunately gout becomes more frequent in transplant 
recipients. Minimizing diuretic use and calcineurin dose 
seems to be important in renal transplant recipients. The 
management of gout in transplant patients can be difficult 
and has been reviewed.224,225
Although allopurinol and uricosuric agents may be used 
together, it is worth noting that uricosuric agents also tend 
to increase the excretion of oxypurinol, resulting in either a 
reduction of efficacy or a need for additional allopurinol.
The prescribing information Dosage and Administration 
section notes that the average dose is 400 to 600 mg/day 
for patients with moderately severe tophaceous gout (and 
presumably with normal renal function). Doses above 
400 mg/day should be administered in divided doses. It is 
best to begin with 100 mg/day to minimize the risk of acute 
gout attacks and increase by 100 mg/day per week. The effect 
of any given dose adjustment upon serum uric acid level 
will generally be apparent by 1 week, occasionally longer 
if many tophaceous deposits are present. The maximum 
recommended dose is 800 mg/day.
Allopurinol has life-threatening interactions with aza-
thioprine and 6-mercaptopurine because metabolism of these 
immunosuppressive agents is inhibited by allopurinol, but 
they may be used together with proper dosage adjustment. 
Allopurinol may prolong anticoagulation times in those 
taking warfarin and may elevate theophylline levels by 
inhibiting metabolism of this purine derivative.
Neither allopurinol nor febuxostat is indicated for 
asymptomatic hyperuricemia, although this was fairly com-
mon practice in years past.226,227 Given the emerging risks of 
sustained hyperuricemia,16,64,228 debate on this question may 
be renewed, but the benefits of lowering uric acid must be 
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Febuxostat
Febuxostat was approved in the US in 2008, the first FDA-
approved hypouricemic agent in more than 40 years. It is a 
nonpurine inhibitor of xanthine oxidase. It has several potential 
advantages over allopurinol including tolerability in those who 
are allopurinol-hypersensitive, better retention of efficacy in 
renal insufficiency (without an increased incidence of hyper-
sensitivity reactions, based on limited data), better efficacy than 
allopurinol in many persons and possibly more rapid dissolution 
of tophi. Potential problems include liver enzyme elevation, 
possibly more gastrointestinal symptomatology than with 
allopurinol and a small increase in the risk of vascular events 
compared with allopurinol. Questions that are still unanswered 
include dose and efficacy in patients with advanced renal failure 
or on dialysis, and whether there are special hazards in this 
population. Clinical trials are ongoing in this population.
Information on efficacy in persons with normal renal 
function comes from a short-term, randomized controlled 
trial.229 The primary endpoint for the trial was the proportion 
of patients with a serum uric acid level 6.0 mg/dL. This 
endpoint was achieved by 56%, 76% and 94% of those taking 
40 mg, 80 mg and 120 mg/day of febuxostat, respectively, 
and by 0% in the placebo group. Perhaps surprisingly, the rate 
of gout flares in the 40 mg group (35%) was similar to that 
in the placebo group (37%). The rate of gout flares increased 
to 55% in those taking 120 mg. Concomitant colchicine 
provided effective prophylaxis against flares, reducing the 
rate to 8% to 13%. Doses of febuxostat approved in the US 
are 40 mg and 80 mg/day.
A subsequent 1-year trial compared doses of 80 mg and 
120 mg with allopurinol 300 mg.230 Entry criteria included 
a serum uric acid .8.0 mg/dL and a serum creatinine 
1.50 mg/dL. (This study has been criticized because the dose 
of allopurinol could not be increased, as it typically would in 
real life). By the final visit, a serum uric acid level 6.0 mg/dL 
was achieved by 81%, 82% and 39%, respectively. In subjects 
with a baseline serum uric acid level .10.0 mg/dL, the primary 
endpoint was achieved by 47%, 44% and 8% respectively. 
There was a trend toward more rapid dissolution of tophi in 
the febuxostat groups (83% reduction in tophus surface area 
in the 40 mg febuxostat group versus 50% reduction in the 
allopurinol group), although this difference did not achieve 
statistical significance, perhaps because a relatively small 
percentage of subjects had tophi at baseline. (Our observa-
tions in clinical practice suggest that febuxostat dissolves 
tophi significantly faster than allopurinol.) There were more 
rashes in the allopurinol group. The incidence of liver enzyme 
elevation was similar in all 3 groups. It is difficult to know if 
febuxostat is superior to allopurinol in dissolving tophi since 
the dose of allopurinol was not increased beyond 300 mg/day, 
as it would be in real life.
Doses above 120 mg/day did not significantly reduce 
uric acid further.231
According to the package insert, there are insufficient 
data to make a recommendation in patients with severe renal 
insufficiency (30 mL/min), and “caution is advised,” but 
it is not considered a contraindication.179 The Cmax and area 
under the plasma concentration time curve for febuxostat and 
for 3 active metabolites are increased in severe renal insuf-
ficiency. There are no published data in patients receiving 
dialysis.179
Febuxostat works fairly quickly; treatment begins with 
40 mg/day. If serum uric acid is not less than 6.0 mg/dL by 
2 weeks, the dose may be increased to 80 mg/day. Mean reduc-
tion in serum uric acid level is 40% and 56% at 40 mg/day 
and 80 mg/day respectively and is similar in those with and 
without renal insufficiency, in contrast to allopurinol. Half-
life of the parent compound and of major metabolites is 
significantly prolonged in persons with renal insufficiency, 
but this does not appear to be clinically important. Elimina-
tion is partially hepatic, allowing greater dosage flexibility in 
those with renal impairment. Transaminase elevation greater 
than 3 times the upper limit of normal occurs in 2% to 3% 
of patients and is similar in this regard to allopurinol. It is 
recommended to follow liver enzymes periodically, certainly 
by 2 months after beginning treatment.
The association of cardiovascular events (cardiovascular 
death, nonfatal myocardial infarction and nonfatal stroke) with 
allopurinol treatment remains unsettled. In Phase 3   studies, 
rates of events per 100 patient-years of exposure were: 
placebo 0, febuxostat 40 mg 0, febuxostat 80 mg 1.09 and 
allopurinol 0.60.179 In long-term extension studies, the rates 
were 0.97 for febuxostat 80 mg and 0.58 for allopurinol (there 
was no placebo group). In all these cases the confidence 
intervals overlapped, but there seems to be a trend. As noted 
in the package insert,179 a causal relationship has not been 
established. Cardiovascular disease is not a contraindication 
to the use of febuxostat or allopurinol, but the febuxostat pack-
age insert further recommends that the practitioner “monitor 
for signs and symptoms of MI and stroke”.179 Given the abil-
ity of both febuxostat and allopurinol to dissolve tophi, it is 
hypothesized that these agents may destabilize plaque (which 
may contain urate) in the walls of blood vessels.
Febuxostat is expected to be at least as effective as 
allopurinol for prophylaxis of nephrolithiasis, based on its 
mechanism of action.International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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Because febuxostat is a xanthine oxidase inhibitor, it 
prolongs the half-life of purine analogs such as azathio-
prine and 6-mercaptopurine and theophylline, similar to the 
case with allopurinol. This is a potentially life-threatening 
interaction, and according to the package insert, febuxostat 
is contraindicated with the above 3 drugs. Hypersensitivity 
to allopurinol is not a contraindication to use of febuxostat.
Febuxostat is more expensive than generic allopurinol, 
costing approximately US$166 for 30 tablets.
In clinical trials, adverse effects associated with febuxo-
stat included rash (2% incidence), but without reported 
severe cutaneous reactions. Incidence of rash with febuxostat 
80 mg/day was similar to that with allopurinol 300 mg/day. 
Diarrhea and elevated hepatic transaminases occurred in 
small proportions of patients. In current clinical practice, to 
contain drug costs, the primary use of febuxostat is reserved 
for patients with allopurinol hypersensitivity, intolerance, or 
treatment failure, including those in whom uricosuric therapy 
is not indicated or has failed.
Probenecid
Hyperuricemia in the vast majority (85% to 90%) of gouty 
patients results from impaired renal uric acid excretion 
rather than from overproduction.232 In these individuals, 
renal uric acid clearance is subnormal (6 mL/min), so that 
maintenance of the balance between urate production and 
disposal can be achieved only at a saturating serum urate 
level, a circumstance predisposing to urate crystal formation 
and deposition. Although uricosuric agents provide a rational 
and even preferable means to lower serum uric acid in these 
patients, this class of urate-lowering agents is prescribed 
infrequently in the US.201 In general, the ideal candidate 
for a uricosuric agent is the gouty patient who is younger 
than 60 years of age, has a creatinine clearance greater than 
80 mL/min, a 24-hour urinary uric acid excretion of less than 
800 mg on a general diet and no history of renal calculi.
Probenecid is the only potent uricosuric agent available 
in the US. It acts by interfering with renal urate or anion 
exchange, thus inhibiting proximal tubular uric acid reab-
sorption.88 The infrequent use of probenecid (5% of treated 
gout patients) likely reflects several circumstances: the 
availability of allopurinol and febuxostat; the requirement for 
multiple daily dosing; diminished or complete loss of urate-
lowering efficacy in gout patients with moderate or more 
advanced CKD; relative contraindication in patients with 
prior urolithiasis or uric acid overproduction; a perception 
that it is less effective than allopurinol; many drug–drug 
interactions. The maintenance dosage of probenecid ranges 
from 500 mg/day to 3.0 g/day and must be taken in divided 
doses. Rash, gastrointestinal complaints and hypersensi-
tivity occur in approximately 5% of patients. Although 
serious toxicity is rarely reported (it is perceived as safer 
than allopurinol in that regard), approximately one-third of 
patients become intolerant and discontinue it.
Alkalinization of the urine has been recommended when 
using a uricosuric agent to decrease the risk of forming uric 
acid calculi. Some authors believe that adequate hydration 
may be sufficient to avoid this complication.
Benzbromarone
Benzbromarone, a uricosuric drug not commercially avail-
able in the US and many other countries, is a potent but 
potentially hepatotoxic agent. The drug is metabolized by 
the hepatic cytochrome P450 system and is effective in 
patients with moderate renal impairment. “Standard doses” of 
benzbromarone (100 mg/day) produce greater hypouricemic 
effects than ‘standard doses’ of allopurinol (300 mg/day) or 
probenecid (1000 mg/day).233,234 In a recently published study 
of “allopurinol-intolerant” patients, 92% of patients given 
benzbromarone were successfully treated to sUA 5 mg/dL 
compared with 65% of patients given probenecid.234
Sulfinpyrazone, another uricosuric agent, is no longer 
available in the US, mainly because of the potential for seri-
ous gastrointestinal toxicity.
Losartan and fenofibrate
Losartan and fenofibrate are drugs developed for indications 
other than urate-lowering but have modest uricosuric effects. 
They are thus useful urate-lowering adjuncts in selected 
patients. Urate-lowering effects of fenofibrate or losartan are 
generally in the range of 12% to 20%, respectively.235
effect of aspirin
Aspirin has a urate-retaining effect on the kidney at low 
doses (3 g/day), but a marked uricosuric effect at high 
doses (.3 g/day). Even mini-dose aspirin can affect serum 
uric acid. In one study of elderly patients, aspirin in a dose 
of 75 mg/day raised sUA by 0.27 mg/dL, 150 mg/day raised 
it less and 325 mg/day did not raise sUA.10 Creatinine 
clearance declined 12% to 13% regardless of dose, cor-
responding to a serum creatinine rise of ∼0.04 mg/dL. 
Interestingly, significant effects on creatinine clearance 
were largely confined to subjects with lower serum albumin 
levels, presumably because of higher free salicylate levels 
in that group. Concomitant diuretic use seemed to increase 
the aspirin effect.International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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Uricase
Uricase could enable accelerated dissolution of tophi over 
intervals of weeks or months instead of years. Uricase has 
the potential to dramatically improve the chronic crippling 
effects of tophaceous gout in those who are intolerant or 
unresponsive to current therapies.
Pegylation of uricase helps to suppress its immunogenicity 
and to increase its half-life. In one pivotal, Phase 3 study in 
patients with particularly severe gout, ∼70% of whom had 
visible tophi, treatment with recombinant, pegylated intra-
venous uricase (pegloticase) 8 mg every 2 weeks achieved 
the target serum uric acid level of 6 mg/dL at 6 months in 
∼42%.12 This regimen also achieved complete resolution of 
tophi in 20% of patients by 13 weeks and ∼40% by 25 weeks. 
The immunogenicity of uricases, including pegloticase, has 
limited their tolerability and efficacy. Antibodies to these 
drugs develop in most patients, despite the use of pegyla-
tion, and infusion reactions are common. Such reactions 
were observed in more than a quarter of patients. High 
titers of antipegloticase antibodies were linked with infusion 
reactions and were often associated with loss of efficacy. 
An important point to note is that in the first few months 
of pegloticase therapy, acute gout flares are frequent, up to 
80% of patients in one study12 but taper off with continued 
therapy in responders.
Uricase treatment has the capability to induce oxidative 
stress mediated by generation of hydrogen peroxide.236 The 
presence of glucose-6-phosphate dehydrogenase deficiency 
is an exclusion criterion for uricase treatment, to prevent 
drug-induced methemoglobinemia and hemolysis. Short-
term and long-term safety are not yet clearly defined for 
uricase therapy. It has been proposed that uricase therapy 
should be reserved for selected patients who could potentially 
benefit from accelerated tophus debulking, for example, to 
resolve incapacitating tophi linked with active synovitis, or 
under circumstances where patients have failed to respond 
to appropriate doses of oral urate-lowering therapies. At the 
time of writing (August, 2010) pegloticase (Krystexxa™; 
Savient Pharmaceuticals, Inc.) has been resubmitted to the 
FDA for approval for selected gout indications.
RDeA594
The critical importance of URAT-1 to uric acid homeostasis 
has made it a prime target for therapeutic manipulation. 
RDEA594 is a novel inhibitor of URAT-1 that was recently 
found in a Phase 2a trial to perform about as well as the 
allopurinol comparator, and was well tolerated.237 Studies 
are ongoing. RDEA594 is a major metabolite of RDEA806, 
a non-nucleoside reverse transcriptase inhibitor currently in 
trials for treatment of HIV .238
Chronic kidney disease and renal 
transplant patients
Treatment of the acute gout attack in patients with renal 
insufficiency has been recently reviewed.215 NSAIDs are 
frequently not an option in such cases. Colchicine may be 
used, but the maintenance dose must be reduced. There is a 
real long-term risk of myopathy and/or neuropathy in renal 
insufficiency with maintenance doses as low as 1.2 mg/day, 
even with relatively short courses. Cyclosporine also interacts 
with colchicine to increase colchicine levels. Corticosteroids 
frequently become the agents of choice. While local joint 
injections result in the least systemic exposure, systemic 
steroids are frequently necessary. Systemic corticosteroids 
must be administered in divided doses 2 or even 3 times per 
day to achieve rapid control.
Whereas most gouty dialysis patients enjoy a marked reduc-
tion in the frequency of gout attacks, the opposite occurs post-
kidney transplant. Patients receiving cyclosporine have been 
reported to have an incidence between 3.5% and 28%; without 
cyclosporine the incidence is between 0% and 8%. Several 
mechanisms of action have been proposed.215,225 Tacrolimus is 
slightly less offensive in its effect on uric acid handling.215
There are no published data on the use of febuxostat in 
transplant patients. Allopurinol remains the hypouricemic 
agent of choice as a rule, but there is a potentially life-
threatening interaction with azathioprine, as noted above.
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